These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29022072)

  • 1. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.
    Bandini M; Smith A; Zaffuto E; Pompe RS; Marchioni M; Capitanio U; Chun FK; Kapoor AB; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2018 Jan; 36(1):51-57. PubMed ID: 29022072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
    Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT
    Marchioni M; Bandini M; Pompe RS; Martel T; Tian Z; Shariat SF; Kapoor A; Cindolo L; Briganti A; Schips L; Capitanio U; Karakiewicz PI
    BJU Int; 2018 Mar; 121(3):383-392. PubMed ID: 28940649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma.
    Nazzani S; Mazzone E; Preisser F; Tian Z; Mistretta FA; Shariat SF; Montanari E; Acquati P; Briganti A; Saad F; Carmignani L; Karakiewicz PI
    Eur J Surg Oncol; 2019 Jul; 45(7):1238-1245. PubMed ID: 30563773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
    Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
    Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma.
    Chakiryan NH; Acevedo AM; Garzotto MA; Chen Y; Liu JJ; Isharwal S; Amling CL; Kopp RP
    Urol Oncol; 2020 Jun; 38(6):604.e1-604.e7. PubMed ID: 32241693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
    Brookman-May SD; May M; Wolff I; Zigeuner R; Hutterer GC; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Feciche B; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Zastrow S; Wirth M; Sountoulides P; Shariat S; Waidelich R; Stief C; Gunia S; ;
    Eur Urol; 2015 May; 67(5):943-51. PubMed ID: 25684695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma.
    Muttin F; Pecoraro A; Larcher A; Dell'Oglio P; Nini A; Cianflone F; Trevisani F; Dehò F; Briganti A; Salonia A; Montorsi F; Bertini R; Capitanio U
    World J Urol; 2019 Apr; 37(4):701-708. PubMed ID: 30046844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma.
    Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Urol Oncol; 2020 May; 38(5):537-544. PubMed ID: 32122729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.
    Russell CM; Lebastchi AH; Chipollini J; Niemann A; Mehra R; Morgan TM; Miller DC; Palapattu GS; Hafez KS; Sexton WJ; Spiess PE; Weizer AZ
    Urology; 2018 Jul; 117():95-100. PubMed ID: 29678662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma: Outcomes According to Surgical Technique and Predictors of Upstaging.
    Jeong SH; Kim JK; Park J; Jeon HJ; Yoon MY; Jeong CW; Ku JH; Kim HH; Kwak C
    PLoS One; 2016; 11(11):e0166183. PubMed ID: 27861519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--Impact on prognosis.
    Becker A; Hickmann D; Hansen J; Meyer C; Rink M; Schmid M; Eichelberg C; Strini K; Chromecki T; Jesche J; Regier M; Randazzo M; Tilki D; Ahyai S; Dahlem R; Fisch M; Zigeuner R; Chun FK
    Eur J Surg Oncol; 2016 Mar; 42(3):419-25. PubMed ID: 26520403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria.
    Hamilton ZA; Capitanio U; Pruthi D; Ghali F; Larcher A; Patel DN; Eldefrawy A; Patel S; Cotta BH; Bradshaw AW; Meagher MF; Miller NS; Carenzi C; Wan F; Liss MA; McGregor T; Montorsi F; Derweesh IH
    Urology; 2020 Apr; 138():60-68. PubMed ID: 31836465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
    Lara PN; Tangen C; Heath EI; Gulati S; Stein MN; Meng M; Alva AS; Pal SK; Puzanov I; Clark JI; Choueiri TK; Agarwal N; Uzzo R; Haas NB; Synold TW; Plets M; Vaishampayan UN; Shuch BM; Lerner S; Thompson IM; Ryan CW
    Eur Urol; 2024 Sep; 86(3):258-264. PubMed ID: 38811313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.
    Eminaga O; Akbarov I; Wille S; Engelmann U
    Int Urol Nephrol; 2015 Oct; 47(10):1653-63. PubMed ID: 26329746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.
    Bedke J; Buse S; Pritsch M; Macher-Goeppinger S; Schirmacher P; Haferkamp A; Hohenfellner M
    BJU Int; 2009 May; 103(10):1349-54. PubMed ID: 19076147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.